Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0M4PH
|
||||
Former ID |
DIB009174
|
||||
Drug Name |
LOXO-101
|
||||
Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [524734] | ||
Company |
Array biopharma; loxo oncology
|
||||
Structure |
Download2D MOL |
||||
Target and Pathway | |||||
Target(s) | BDNF/NT-3 growth factors receptor | Target Info | Inhibitor | [543504] | |
Trk receptor | Target Info | Inhibitor | [532994] | ||
Neurotrophic tyrosine kinase receptor 1 | Target Info | Inhibitor | [551954] | ||
NetPath Pathway | IL2 Signaling Pathway | ||||
References | |||||
Ref 532994 | ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39. | ||||
Ref 543504 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818). | ||||
Ref 551954 | Clinical pipeline report, company report or official report of Loxo Oncology. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.